Round cell liposarcoma
diseaseOn this page
Also known as cellular myxoid liposarcomaround cell liposarcoma (morphologic abnormality)
Summary
Round cell liposarcoma (MONDO:0005238) is a disease and 6 clinical trials. Top therapeutic interventions include interferon gamma-1b, nogapendekin alfa inbakicept, and pembrolizumab. A subtype of myxoid/round cell liposarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | round cell liposarcoma |
| Mondo ID | MONDO:0005238 |
| EFO | EFO:0003084 |
| DOID | DOID:5692 |
| NCIT | C4252 |
| SNOMED CT | 404070007 |
| UMLS | C0334471 |
| MedGen | 90787 |
| GARD | 0024169 |
| Is cancer (heuristic) | no |
Also known as: cellular myxoid liposarcoma · round cell liposarcoma · round cell liposarcoma (morphologic abnormality)
Disease family
This is a subtype of myxoid/round cell liposarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › lipomatous cancer › liposarcoma › myxoid/round cell liposarcoma › round cell liposarcoma
Related subtypes (1): myxoid liposarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06843967 | PHASE1/PHASE2 | RECRUITING | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma |
| NCT03063632 | PHASE2 | COMPLETED | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma |
| NCT03397186 | PHASE2 | WITHDRAWN | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma |
| NCT03670069 | PHASE1 | TERMINATED | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas |
| NCT07261657 | EARLY_PHASE1 | RECRUITING | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy |
| NCT01957709 | EARLY_PHASE1 | TERMINATED | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| INTERFERON GAMMA-1B | 4 | 1 |
| NOGAPENDEKIN ALFA INBAKICEPT | 4 | 1 |
| PEMBROLIZUMAB | 4 | 1 |
| TRABECTEDIN | 4 | 1 |
| ITACITINIB | 3 | 1 |
| MIRDAMETINIB | 2 | 1 |